Ishikura Kenji, Omae Kenji, Sasaki Sho, Shibagaki Yugo, Ichioka Satoko, Okuda Yusuke, Koitabashi Kenichiro, Suyama Koichi, Mizukami Takuro, Kondoh Chihiro, Hirata Sumio, Matsubara Takeshi, Hoshino Junichi, Yanagita Motoko
Department of Pediatrics, Kitasato University School of Medicine, Kawasaki, Japan.
Department of Innovative Research and Education for Clinicians and Trainees, Fukushima Medical University Hospital, Fukushima, Japan.
Int J Clin Oncol. 2023 Oct;28(10):1333-1342. doi: 10.1007/s10147-023-02375-1. Epub 2023 Jul 7.
Chronic kidney disease (CKD) is one of the most disabling disorders with significant comorbidity and mortality. Incidence and prevalence of CKD in cancer survivors are remarkably high in both adults and pediatric patients. The reasons for this high incidence/prevalence are multifold but kidney damage by cancer itself and cancer treatment (pharmacotherapy/surgery/radiation) are the main reasons. Since cancer survivors commonly have significant comorbidities, risk of cancer recurrence, limited physical function or life expectancy, special attentions should be paid when considering the treatment of CKD and its complications. Especially, shared decision-making should be considered when selecting the renal replacement therapies with as much information/facts/evidence as possible.
慢性肾脏病（CKD）是最具致残性的疾病之一，具有显著的合并症和死亡率。CKD在成年和儿科癌症幸存者中的发病率和患病率都非常高。这种高发病率/患病率的原因是多方面的，但癌症本身和癌症治疗（药物治疗/手术/放疗）导致的肾损伤是主要原因。由于癌症幸存者通常有明显的合并症、癌症复发风险、身体功能或预期寿命受限，在考虑CKD及其并发症的治疗时应给予特别关注。特别是，在选择肾脏替代治疗时，应尽可能多地依据信息/事实/证据进行共同决策。
